<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02103374</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN10-PD/Nebuadom</org_study_id>
    <secondary_id>2010-023743-14</secondary_id>
    <secondary_id>2010-R38</secondary_id>
    <secondary_id>A101466-30</secondary_id>
    <nct_id>NCT02103374</nct_id>
  </id_info>
  <brief_title>Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State</brief_title>
  <acronym>Nebuadom</acronym>
  <official_title>Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Design studies of nebulization in COPD does not respond adequately to the clinically
      relevant question: the intervention of administering nebulized bronchodilators at home it is
      likely to make a profit, compared to the standard optimized treatment as defined by the
      recommendations of the SPLF, patients with severe COPD (stage III, FEV between 30% and 50%
      of the theoretical value) and very severe (stage IV, less than 30% of the theoretical value
      FEV)? The concept of profit in this context is based on criteria of dyspnea, quality of
      life, use of health system (exacerbations, hospitalizations, prescription of antibiotics and
      steroids ...).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Score for quality of life, assessed by the questionnaire St Georges</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score for quality of life, assessed by the questionnaire VQ11</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score according Medical Research Council</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic Score Mortality assessed by the score BODE</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospitalizations</measure>
    <time_frame>Patients will be followed for the duration of their participation ie 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Severe Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Atrovent + Bricanyl or Atrovent + Ventolin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule per day lactose (in addition to the standard optimized treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrovent + Bricanyl or Atrovent + Ventoline</intervention_name>
    <description>3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks</description>
    <arm_group_label>Atrovent + Bricanyl or Atrovent + Ventolin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule lactose during 48 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  COPD Patients stage 3 et 4

          -  Has not submitted an exacerbation in the 3 months preceding the pre-inclusion visit

          -  Weaned from tobacco for at least 6 months

          -  vaccinated against pneumococcal

          -  Have not been included in a pulmonary rehabilitation program during the 6 months
             preceding the screening visit inclusion

          -  Patient pre-included not showing exacerbation since the pre-inclusion visit

        Exclusion Criteria:

          -  Patient under nebulizer or has been treated with nebulized bronchodilators at home
             over the last 6 months

          -  Patient with an indication of oxygen is expected in the coming year

          -  Progressive malignant disease known

          -  Patient under non-invasive ventilation (NIV) for less than 6 months or NIV provided
             in the following year

          -  Patient known to be colonized by Pseudomonas aeruginosa, A. xylosoxidans,
             Burkholderia cepacia or Stenotrophomonas maltophilia

          -  Patients with severe cardiovascular disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice DIOT, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrice DIOT, MD-PhD</last_name>
    <phone>+33 (0)2 47 47 80 32</phone>
    <email>diot@med.univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie COUDRAY</last_name>
    <phone>+33 (0)2 47 47 46 64</phone>
    <email>marie.coudray@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Alexandre ROGER</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Alexandre ROGER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric GAGNADOUX, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric GAGNADOUX, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude BARNIER</last_name>
    </contact>
    <investigator>
      <last_name>Aude BARNIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien QUETANT</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien QUETANT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris MELLONI, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Boris MELLONI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François CHABOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>François CHABOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud CAVAILLES</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud CAVAILLES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand LEMAIRE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand LEMAIRE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas ROCHE, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas ROCHE, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice CARON</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice CARON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François LEBARGY, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>François LEBARGY, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François MUIR, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François MUIR, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice DIOT, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Patrice DIOT, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>weaned tobacco</keyword>
  <keyword>Has not submitted an exacerbation in the past 3 months</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
